These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34589958)

  • 21. Landscape of Acquired Resistance to Osimertinib in
    Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
    Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Zeng Z; Wang T; He J; Wang Y
    Front Oncol; 2022; 12():1010084. PubMed ID: 36387181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
    Choudhury NJ; Marra A; Sui JSY; Flynn J; Yang SR; Falcon CJ; Selenica P; Schoenfeld AJ; Rekhtman N; Gomez D; Berger MF; Ladanyi M; Arcila M; Rudin CM; Riely GJ; Kris MG; Heller G; Reis-Filho JS; Yu HA
    J Thorac Oncol; 2023 Apr; 18(4):463-475. PubMed ID: 36494075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.
    Zhu L; Chen Z; Zang H; Fan S; Gu J; Zhang G; Sun KD; Wang Q; He Y; Owonikoko TK; Ramalingam SS; Sun SY
    Cancer Res; 2021 Sep; 81(18):4822-4834. PubMed ID: 34289988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.
    Ou SI; Cui J; Schrock AB; Goldberg ME; Zhu VW; Albacker L; Stephens PJ; Miller VA; Ali SM
    Lung Cancer; 2017 Jun; 108():228-231. PubMed ID: 28625641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer.
    Liu Z; Dong H; Chen W; Wang B; Ji D; Zhang W; Shi X; Feng X
    Front Med (Lausanne); 2022; 9():906364. PubMed ID: 35872785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
    Chen N; Tyler LC; Le AT; Welsh EA; Fang B; Elliott A; Davies KD; Danhorn T; Riely GJ; Ladanyi M; Haura EB; Doebele RC
    Mol Cancer Ther; 2024 Jan; 23(1):92-105. PubMed ID: 37748191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
    Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
    BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.
    Nie K; Jiang H; Zhang C; Geng C; Xu X; Zhang L; Zhang H; Zhang Z; Lan K; Ji Y
    Biomed Res Int; 2018; 2018():9010353. PubMed ID: 29713646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
    Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
    Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports.
    Michaux L; Perrier A; Mehlman C; Alshehhi H; Dubois A; Lacave R; Coulet F; Cadranel J; Fallet V
    Front Oncol; 2023; 13():1182558. PubMed ID: 37448514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib.
    Gu J; Qian L; Zhang G; Mahajan NP; Owonikoko TK; Ramalingam SS; Sun SY
    Lung Cancer; 2020 Dec; 150():26-35. PubMed ID: 33049499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib.
    Thomas D; Maloney ME; Raval G
    Cureus; 2023 Nov; 15(11):e48122. PubMed ID: 38046784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.
    Vojnic M; Kubota D; Kurzatkowski C; Offin M; Suzawa K; Benayed R; Schoenfeld AJ; Plodkowski AJ; Poirier JT; Rudin CM; Kris MG; Rosen NX; Yu HA; Riely GJ; Arcila ME; Somwar R; Ladanyi M
    J Thorac Oncol; 2019 May; 14(5):802-815. PubMed ID: 30831205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
    Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
    Chen J; Facchinetti F; Braye F; Yurchenko AA; Bigot L; Ponce S; Planchard D; Gazzah A; Nikolaev S; Michiels S; Vasseur D; Lacroix L; Tselikas L; Nobre C; Olaussen KA; Andre F; Scoazec JY; Barlesi F; Soria JC; Loriot Y; Besse B; Friboulet L
    Ann Oncol; 2022 Apr; 33(4):434-444. PubMed ID: 35066105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.